Illustrative image.

Xeljanz

Name: Xeljanz
Brand: Pfizer
Availability: InStock

Tofacitinib citrate

Prescription required

$1536.00

5mg · 3 × 56 tablets · 3 months supply

BrandBranded medicine· By Pfizer

$512.00 per month

Strength

How long a supply?

1 month$512.00 a monthOne-off$512.00

3 months$512.00 a monthOne-off$1536.00

6 months$512.00 a monthOne-off$3072.00

Supplied from Turkey

Test mode: no payment is taken. View cart

Annual cost

$6656a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

5mg

11mg

FDA boxed warningSerious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis

Increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), leading to hospitalization or death. Interrupt XELJANZ/XELJANZ XR treatment if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test.

Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients.

Malignancies have occurred in patients treated with XELJANZ. Higher rate of lymphomas and lung cancers with XELJANZ vs. TNF blockers in RA patients.

Higher rate of major adverse CV events (defined as CV death, myocardial infarction, and stroke) with XELJANZ vs. TNF blockers in RA patients.

Thrombosis has occurred in patients treated with XELJANZ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with XELJANZ vs. TNF blockers in RA patients.

Read this with the rest of the clinical information

About Xeljanz

Overview

Xeljanz tablets contain tofacitinib citrate, a Janus kinase (JAK) inhibitor. They are used in adults with moderately to severely active rheumatoid arthritis or ulcerative colitis, active psoriatic arthritis, or active ankylosing spondylitis when one or more TNF blockers have not worked well enough or could not be tolerated. Xeljanz immediate-release tablets are also used in children aged 2 years and older with active psoriatic arthritis or active polyarticular course juvenile idiopathic arthritis under the same conditions. Tofacitinib works by blocking JAK enzymes that carry signals involved in immune cell activity.

What it treats

For adults who have not responded adequately to, or cannot tolerate, one or more TNF blockers: • Moderately to severely active rheumatoid arthritis. • Active psoriatic arthritis. • Active ankylosing spondylitis. • Moderately to severely active ulcerative colitis. Xeljanz tablets are also used in children aged 2 years and older who have not responded adequately to, or cannot tolerate, one or more TNF blockers: • Active psoriatic arthritis. • Active polyarticular-course juvenile idiopathic arthritis.

Safety information

Side effects

Common side effects include upper respiratory tract infections, cold-like symptoms, diarrhoea and headache. In adults treated for ulcerative colitis, common side effects also include raised cholesterol, increased blood creatine phosphokinase, rash and shingles. Common side effects in children with polyarticular-course juvenile idiopathic arthritis are consistent with those reported in adults with rheumatoid arthritis. Serious risks include serious infections, cancer and disorders involving abnormal growth of lymphatic cells, major cardiovascular events, blood clots, holes in the stomach or intestines, and allergic reactions. The label also warns of an increased risk of death. Contact a doctor promptly if you develop a serious infection, new abdominal symptoms, or symptoms of an allergic reaction, cardiovascular event or blood clot. Low blood sugar can occur in people with diabetes. Tell your healthcare provider if you develop symptoms of low blood sugar; more frequent blood glucose checks may be needed. Treatment can also affect white blood cell counts, haemoglobin, liver enzymes and blood fats, so laboratory monitoring is recommended.

FDA boxed warning

Serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis

Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients.

Malignancies have occurred in patients treated with XELJANZ. Higher rate of lymphomas and lung cancers with XELJANZ vs. TNF blockers in RA patients.

Higher rate of major adverse CV events (defined as CV death, myocardial infarction, and stroke) with XELJANZ vs. TNF blockers in RA patients.

Thrombosis has occurred in patients treated with XELJANZ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with XELJANZ vs. TNF blockers in RA patients.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

• Seek medical attention promptly for new stomach pain or other new abdominal symptoms, especially if you are at increased risk of a tear in the stomach or bowel. • If you have diabetes, contact your doctor if you develop signs or symptoms of low blood sugar.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The label lists no formal contraindications. However, Xeljanz should be avoided during an active serious infection, including a serious infection limited to one area of the body. People at increased risk of a tear in the stomach or intestine need prompt medical assessment if new abdominal symptoms develop. People with diabetes may need more frequent blood glucose checks and should tell their healthcare provider if they develop signs or symptoms of low blood sugar. Laboratory monitoring is recommended because treatment may change certain white blood cell counts, haemoglobin, liver enzymes and blood fats. Avoid live vaccines during treatment. Do not breastfeed while taking this medicine.

Interactions

Ketoconazole and fluconazole can increase the amount of tofacitinib in the body. Your prescriber may need to adjust your dose if you take these medicines. Rifampin can lower the amount of tofacitinib in the body and may reduce its effect. Taking it with Xeljanz is not recommended. Taking Xeljanz with biologic disease-modifying antirheumatic drugs (DMARDs) or potent immune-suppressing medicines, such as azathioprine, tacrolimus or cyclosporine, is not recommended because of the risk of added immune suppression. Tell your doctor if you take any of these medicines.

Using Xeljanz

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original blister until you take a dose, away from direct light and moisture. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label XELJANZ (TOFACITINIB) TABLET, FILM COATED XELJANZ XR (TOFACITINIB) TABLET, EXTENDED RELEASE XELJANZ (TOFACITINIB) SOLUTION [U.S. PHARMACEUTICALS] (DailyMed, retrieved 19 September 2026).

Patient information and references

Official and supporting information to read alongside advice from your prescriber or pharmacist.

Patient information leaflet (PDF)

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.